NcXHF

GERBER, PAIK, AND DOWLATI
enzyme inhibitor, veliparib, potentiates chemotherapy and radiation
in vitro and in vivo in small cell lung cancer. Cancer Med. 2014;3:1579-
1594.
66. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with
small-cell lung cancer: association with complete response to therapy
and improved survival. J Clin Oncol. 1997;15:2866-2872.
67. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with
paclitaxel and carboplatin as fırst-line therapy in extensive-diseasesmall-cell
lung cancer: results from a randomized, double-blind, multicenter
phase 2 trial. Ann Oncol. 2013;24:75-83.
68. Schultheis AM, Scheel AH, Ozretic L, et al. PD-L1 expression in small
cell neuroendocrine carcinomas. Eur J Cancer. 2015;51:421-426.
69. Nickolich M, Babakoohi S, Fu P, et al. Clinical trial design in small cell
lung cancer: surrogate end points and statistical evolution. Clin Lung
Cancer. 2014;15:207-212.
70. Quaedvlieg PF, Visser O, Lamers CB, et al. Epidemiology and survival
in patients with carcinoid disease in The Netherlands. An epidemiological
study with 2391 patients. Ann Oncol. 2001;12:1295-1300.
71. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid
tumors. Cancer. 2003;97:934-959.
72. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology:
contrasting Norway and North America. Cancer. 2008;113:
2655-2664.
73. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”:
epidemiology of and prognostic factors for neuroendocrine tumors in
35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
74. Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and
sur||vival of gastrointestinal neuroendocrine tumors in the United
States: a seer analysis. J Cancer. 2012;3:292-302.
75. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol. 2001;54:
257-271.
76. Banerjee AK. Preinvasive lesions of the bronchus. J Thorac Oncol.
2009;4:545-551.
77. Gorshtein A, Gross DJ, Barak D, et al. Diffuse idiopathic pulmonary
neuroendocrine cell hyperplasia and the associated lung neuroendocrine
tumors: clinical experience with a rare entity. Cancer. 2012;118:
612-619.
78. Cao C, Yan TD, Kennedy C, et al. Bronchopulmonary carcinoid tumors:
long-term outcomes after resection. Ann Thorac Surg. 2011;91:
339-343.
79. Skuladottir H, Hirsch FR, Hansen HH, et al. Pulmonary neuroendocrine
tumors: incidence and prognosis of histological subtypes. A
population-based study in Denmark. Lung Cancer. 2002;37:127-135.
80. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine
carcinoma of the lung: a clinicopathologic study of eighty-seven cases.
J Thorac Cardiovasc Surg. 2002;124:285-292.
81. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms
of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70-76.
82. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation,
diagnosis, and outcome in 142 cases in Israel and review of 640
cases from the literature. Chest. 2001;119:1647-1651.
83. Froudarakis M, Fournel P, Burgard G, et al. Bronchial carcinoids. A
review of 22 cases. Oncology. 1996;53:153-158.
84. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine
tumors. Cancer. 2008;113:5-21.
85. Fischer S, Kruger M, McRae K, et al. Giant bronchial carcinoid tumors:
a multidisciplinary approach. Ann Thorac Surg. 2001;71:386-393.
86. Karmy-Jones R, Vallieres E. Carcinoid crisis after biopsy of a bronchial
carcinoid. Ann Thorac Surg. 1993;56:1403-1405.
87. Mehta AC, Rafanan AL, Bulkley R, et al. Coronary spasm and cardiac
arrest from carcinoid crisis during laser bronchoscopy. Chest. 1999;
115:598-600.
88. Limper AH, Carpenter PC, Scheithauer B, et al. The Cushing syndrome
induced by bronchial carcinoid tumors. Ann Intern Med. 1992;
117:209-214.
89. Jones JE, Shane SR, Gilbert E, et al. Cushing’s syndrome induced by the
ectopic production of ACTH by a bronchial carcinoid. J Clin Endocrinol
Metab. 1969;29:1-5.
90. DeStephano DB, Lloyd RV, Schteingart DE. Cushing’s syndrome produced
by a bronchial carcinoid tumor. Hum Pathol. 1984;15:890-892.
91. Scanagatta P, Montresor E, Pergher S, et al. Cushing’s syndrome induced
by bronchopulmonary carcinoid tumours: a review of 98 cases
and our experience of two cases. Chir Ital. 2004;56:63-70.
92. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis
and treatment. Mayo Clin Proc. 2010;85:838-854.
93. Filosso PL, Donati G, Rena O, et al. Acromegaly as manifestation of a
bronchial carcinoid tumour. Asian Cardiovasc Thorac Ann. 2003;11:
189.
94. Athanassiadi K, Exarchos D, Tsagarakis S, et al. Acromegaly caused by
ectopic growth hormone-releasing hormone secretion by a carcinoid
bronchial tumor: a rare entity. J Thorac Cardiovasc Surg. 2004;128:631-
632.
95. Jeung MY, Gasser B, Gangi A, et al. Bronchial carcinoid tumors of the
thorax: spectrum of radiologic fındings. Radiographics. 2002;22:351-
365.
96. Pasieka JL, McKinnon JG, Kinnear S, et al. Carcinoid syndrome symposium
on treatment modalities for gastrointestinal carcinoid tumours:
symposium summary. Can J Surg. 2001;44:25-32.
97. Thorson AH. Studies on carcinoid disease. Acta Med Scand. 1958;334:
1-132.
98. Righi L, Volante M, Tavaglione V, et al. Somatostatin receptor tissue
distribution in lung neuroendocrine tumours: a clinicopathologic and
immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann
Oncol. 2010;21:548-555.
99. Granberg D, Sundin A, Janson ET, et al. Octreoscan in patients with
bronchial carcinoid tumours. Clin Endocrinol (Oxf). 2003;59:793-799.
100. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors
in surgical and percutaneous needle biopsy samples of carcinoids and
islet cell carcinomas. Cancer Res. 1990;50:5969-5977.
101. Weiss M, Yellin A, Husza’r M, et al. Localization of adrenocorticotropic
hormone-secreting bronchial carcinoid tumor by somatostatinreceptor
scintigraphy. Ann Intern Med. 1994;121:198-199.
102. Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional
imaging to cross-sectional computed tomography or magnetic
resonance imaging for the detection of neuroendocrine tumors: added
value or an anachronism? J Clin Oncol. 2011;29:e74-e75.
103. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity
in patients with metastatic pancreatic neuroendocrine tumors
after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol.
2010;28:69-76.
104. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful
marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967-1973.
105. Terzi A, Lonardoni A, Feil B, et al. Bronchoplastic procedures for central
carcinoid tumors: clinical experience. Eur J Cardiothrac Surg.
2004;26:1196-1199.
106. El Jamal M, Nicholson AG, Goldstraw P. The feasibility of conservative
resection for carcinoid tumours: is pneumonectomy ever necessary for
uncomplicated cases? Eur J Cardiothrac Surg. 2000;18:301-306.
107. Lucchi M, Melfı F, Ribechini A, et al. Sleeve and wedge parenchymasparing
bronchial resections in low-grade neoplasms of the bronchial
airway. J Thorac Cardiovasc Surg. 2007;134:373-377.
108. Cerfolio RJ, Deschamps C, Allen MS, et al. Mainstem bronchial sleeve
resection with pulmonary preservation. Ann Thorac Surg. 1996;61:
1458-1462.
160 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook